Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 889,895 | 749,284 | 548,485 | 500,723 | 441,358 |
| Cost of Goods | 152,008 | 122,267 | 88,391 | 91,830 | 84,023 |
| Gross Profit | 737,887 | 627,017 | 460,094 | 408,893 | 357,335 |
| Operating Expenses | 848,597 | 720,175 | 616,492 | 519,938 | 391,248 |
| Operating Income | -110,702 | -92,891 | -156,007 | -110,215 | -33,890 |
| Interest Expense | 38,244 | 36,642 | 10,447 | 7,639 | 8,409 |
| Other Income | -5,778 | 4,665 | -10,049 | -424 | -1,328 |
| Pre-tax Income | -154,724 | -124,868 | -176,503 | -118,278 | -43,627 |
| Income Tax | 17,075 | 9,101 | -150 | -3,931 | 10,209 |
| Net Income Continuous | -171,799 | -133,969 | -176,353 | -114,347 | -53,836 |
| Net Income | $-171,799 | $-133,969 | $-176,353 | $-114,347 | $-53,836 |
| EPS Basic Total Ops | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 |
| EPS Basic Continuous Ops | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 |
| EPS Diluted Total Ops | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 |
| EPS Diluted Continuous Ops | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 |
| EBITDA(a) | $-61,338 | $-39,809 | $-114,094 | $-61,411 | $5,192 |